Adagio Medical Holdings, Inc Common Stock logo

Adagio Medical Holdings, Inc Common Stock(ADGM)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.93
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ADGM

11/13/2026: ADGM (1-star) is currently NOT-A-BUY. Pass it for now.

Adagio Medical Holdings, Inc. is a micro-cap medical technology stock focused on developing catheter-based ultra-low temperature ablation systems for cardiac arrhythmias. Its primary strengths lie in its differentiated ULTA technology platform and active clinical trials targeting difficult conditions like ventricular tachycardia. The core investment story centers on achieving regulatory approvals and scaling commercial adoption in high-value electrophysiology markets. However, the company faces substantial execution, competitive, and financing risks given its micro-cap scale and history of net losses. This stock suits speculative growth investors willing to monitor clinical trial readouts and regulatory milestones closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers high-risk exposure to advanced medical device innovations, though commercial scale is still in early stages.
Momentum investorStrong fit while signal remains positiveThe micro-cap stock can experience sharp technical moves driven by clinical trial catalysts or regulatory updates.
Value investorWeak fitNegative earnings and developmental cash burn make traditional value metrics inapplicable.
Dividend investorWeak fitThe company pays no dividends and reinvests all capital into clinical execution.
Low-risk investorWeak fitHigh share price volatility and micro-cap liquidity risks present an aggressive risk profile.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap medical device stocks often experience pronounced intraday swings and sensitivity to news flow.
Valuation riskHighPricing is largely speculative based on future clinical and commercial milestones rather than current earnings.
Competition risk (Medtech incumbents)HighWell-capitalized medical device leaders dominate hospital accounts and electrophysiology product bundling.
Business qualityMediumProprietary technology is scientifically compelling, but early commercial scale is still unproven.
Dividend incomeLow / noneNo dividend payouts are offered or anticipated in the near term.
Execution riskHighSuccess depends heavily on complex clinical trial outcomes, regulatory approvals, and commercial adoption.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.77M USD
Price to earnings Ratio -
1Y Target Price 105
Price to earnings Ratio -
1Y Target Price 105
Volume (30-day avg) 1.7M shares
Beta 0.07
52 Weeks Range 1.50 - 50.70
Updated Date 11/15/2026
52 Weeks Range 1.50 - 50.70
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -41.1

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -63.19%
Avg. Invested days 15
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ADGM receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ADGM has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, strong earnings growth (+53.3%) is partially offset by soft cash generation (FCF margin 0.0%), negative revenue growth (-100.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
ADGM's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is ADGM's strongest growth driver at +53.3% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+37.7%, strong) is also strong, while revenue growth (-100.0%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 53.0% (solid) and 30.7% of outstanding shares are publicly tradable (moderate). Insider ownership is only 0.95%, which materially reduces the ownership score.

Top 5 Institutional Investors

Perceptive Advisors LLC 36.33%
Adage Capital Partners Gp LLC 4.63%
ADAR1 Capital Management LLC 4.43%
Alyeska Investment Group, L.P. 4.27%
Sio Capital Management, LLC 2.57%

Unit Economics (Per $1K Revenue)

★★★★★
ADGM generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
ADGM has a relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Cardiac Ablation Devices (Global)Commercial sales of iCLAS catheters, vCLAS systems, and related consoles and accessories primarily in approved international markets and via expanded access frameworks.The company generates revenue by selling specialized catheter equipment to hospitals for treating complex heart rhythm disorders.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 20.03M
Price to Sales(TTM) 205.85
Enterprise Value 20.03M
Price to Sales(TTM) 205.85
Enterprise Value to Revenue 370.25
Enterprise Value to EBITDA -
Shares Outstanding 914.64K
Shares Floating 281.04K
Shares Outstanding 914.64K
Shares Floating 281.04K
Percent Insiders 0.95
Percent Institutions 53.04

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.